Join the mRNA Vaccine Race With Affinity Purification
White Paper Feb 19, 2021
mRNA based interventions are becoming much more
prevalent in current times, with several leading SARS-CoV-2 vaccines relying on
mRNA technology. Bench-scale mRNA purification methods cannot keep up with
large-scale production of clinical-grade mRNA and consequently developers are
looking to adopt faster, more efficient, highly scalable methods for
purification.
Download this whitepaper to learn
about an affinity-based method that can:
- Streamline the production of mRNA vaccines
- Be readily adopted for biotherapeutic
development
Related White Papers
It is paramount within the pharmaceutical industry that scientists can manage large amounts of data efficiently and safely. The Cubis® II balance series was designed for customizable modularity, meeting the needs of the industry whilst maintaining full compliance.
READ MORESingle-cell sequencing is quickly becoming a standard tool in biological research due to the scale and depth of insight it provides across diverse cell populations. The pharmaceutical industry is exploiting single-cell approaches to identify novel therapeutic targets and accelerate promising assets through development.
READ MOREAccess this whitepaper to discover a system that performs virtual screening at ultra-high-throughput scale, requires minimal costs and can be run with cloud computing or HPC resources.
READ MORELike what you just read? You can find similar content on the communities below.
Biopharma Drug Discovery Genomics Research Immunology & MicrobiologyTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
